WO2009143371A3 - COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF - Google Patents

COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF Download PDF

Info

Publication number
WO2009143371A3
WO2009143371A3 PCT/US2009/044891 US2009044891W WO2009143371A3 WO 2009143371 A3 WO2009143371 A3 WO 2009143371A3 US 2009044891 W US2009044891 W US 2009044891W WO 2009143371 A3 WO2009143371 A3 WO 2009143371A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
mtor sirna
mtor
sirna
Prior art date
Application number
PCT/US2009/044891
Other languages
French (fr)
Other versions
WO2009143371A2 (en
Inventor
Frank Y. Xie
Xiaodong Yang
Original Assignee
Intradigm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corporation filed Critical Intradigm Corporation
Publication of WO2009143371A2 publication Critical patent/WO2009143371A2/en
Publication of WO2009143371A3 publication Critical patent/WO2009143371A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides nucleic acid molecules that inhibit mTOR expression. Methods of using the nucleic acid molecules are also provided.
PCT/US2009/044891 2008-05-21 2009-05-21 COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF WO2009143371A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5495908P 2008-05-21 2008-05-21
US61/054,959 2008-05-21

Publications (2)

Publication Number Publication Date
WO2009143371A2 WO2009143371A2 (en) 2009-11-26
WO2009143371A3 true WO2009143371A3 (en) 2010-01-14

Family

ID=41202671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044891 WO2009143371A2 (en) 2008-05-21 2009-05-21 COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF

Country Status (1)

Country Link
WO (1) WO2009143371A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951787B1 (en) 2016-09-09 2019-03-05 주식회사 큐로진생명과학 Pharmaceutical Composition for Treating Macular Degeneration Containing mTOR Inhibitor
WO2018048046A2 (en) * 2016-09-09 2018-03-15 (주)씨드모젠 Pharmaceutical composition containing mtor inhibitor for treating macular degeneration
US11723912B2 (en) 2016-12-08 2023-08-15 University Of Utah Research Foundation Staufen1 agents and associated methods
US11946046B2 (en) * 2018-06-14 2024-04-02 University Of Utah Research Foundation Staufen1 regulating agents and associated methods
CA3242059A1 (en) * 2021-12-21 2023-06-29 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method thereof and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023202A2 (en) * 2003-09-09 2005-03-17 Beth Israel Deaconess Medical Center, Inc. Tumor suppressor lkb1 kinase directly activates amp-activated kinase
US20060234249A1 (en) * 2005-04-15 2006-10-19 Immusol Incorporated Novel assays for assessing cancerous cell growth
WO2008109364A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023202A2 (en) * 2003-09-09 2005-03-17 Beth Israel Deaconess Medical Center, Inc. Tumor suppressor lkb1 kinase directly activates amp-activated kinase
US20060234249A1 (en) * 2005-04-15 2006-10-19 Immusol Incorporated Novel assays for assessing cancerous cell growth
WO2008109364A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOU ET AL: "An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR", CANCER LETTERS, NEW YORK, NY, US, vol. 253, no. 2, 10 July 2007 (2007-07-10), pages 236 - 248, XP022144286, ISSN: 0304-3835 *
IWAMARU A ET AL: "Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 26, no. 13, 25 September 2006 (2006-09-25), pages 1840 - 1851, XP002497598, ISSN: 0950-9232, [retrieved on 20060925] *
KE N ET AL: "A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 312, no. 15, 10 September 2006 (2006-09-10), pages 2726 - 2734, XP024945163, ISSN: 0014-4827, [retrieved on 20060910] *

Also Published As

Publication number Publication date
WO2009143371A2 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
AU2017248555B2 (en) Closed nucleic acid structures
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2010062863A3 (en) Compositions containing satiogens and methods of use
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2009111676A3 (en) Boron-containing small molecules as anti-inflammatory agents
WO2011156654A3 (en) Pathways characterization of cells
EP2224912A4 (en) Improved compositions and methods for the delivery of nucleic acids
WO2010120853A3 (en) Methods and compositions to detect and differentiate small rnas in rna maturation pathway
WO2013173605A8 (en) Compositions and methods for modulating pten expression
EP2274442A4 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
WO2009111586A3 (en) Autonomous in vitro evolution
WO2010011331A3 (en) Compositions and methods related to sirt1 function
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2010039802A3 (en) Methods and compositions for isolating nucleic acid
WO2009114724A3 (en) COMPOSITIONS COMPRISING NUCLEAR FACTOR-KAPPA B (NF-ĸB) SIRNA AND METHODS OF USE
EP2318508A4 (en) Determination of the integrity of rna
WO2007106915A3 (en) Antibodies to egfl7 and methods for their use
EP2539354A4 (en) Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
WO2009143371A3 (en) COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09751599

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09751599

Country of ref document: EP

Kind code of ref document: A2